Market Pulse: Attractive market opportunities for investors (Opinion)
The S&P 500 and Nasdaq Composite reached new highs, that despite the daily broadside of negative news about the economy, tariffs, trade and growth prospects here and abroad. Investing is all about the future, of course, not this year’s results. That explains why stocks are up.
Although third-quarter earnings are in the daily news, expectations for next year’s profits matter far more. S&P operating earnings next year, assuming no recession, will range from $160 to $180, which means the market is trading for 16-18 times earnings, by historical measures neither cheap nor expensive.
Most analysts would call it fairly valued under normal conditions, but times are not normal given rock-bottom interest rates, the likelihood that they will fall even more, and most important the abnormally unattractive alternatives.
By the way, have you noticed that we no longer hear about the inverted yield curve and its implications? Two reasons. First, the curve’s inversion was brief and focused only on one pair of many maturities. And it is far from inverted now. Second, bad news sells.
While the market is at its high, investors can still buy low. The pharmaceutical sector has lagged other areas, is undervalued relative to the market, and has higher yields. The reason: The drug companies have headwinds in Washington and have for years.
Yes, there will be changes to the way healthcare is accessed and paid for, and there should be. But not to a degree that devastates the industry. Plus, drug and healthcare companies are not at risk due to rising tariffs since China does not want to make badly needed drugs and medical products any more expensive. No one does.
While investors can buy the SPDR S&P Pharmaceuticals ETF (XPH), I hold individual pharmaceutical stocks in my client portfolios. My favorites are Merck (MRK) and Pfizer (PFE), both of which blew past earnings estimates earlier this week. For Merck, Keytruda’s quarterly sales topped $3 billion for first time.
China sales for Merck’s vaccine Gardasil rose 90 percent in the quarter. Pfizer sales of breast-cancer drug Ibrance rose 24 percent to an annual $5.1 billion. Earnings estimates were raised.
Investors can buy the market as it hits new highs using passive mutual funds or ETFs, or if they don’t want to chase strength they can look to the healthcare sector.
Bottom line: There are opportunities for investors, both to buy breakouts and buy laggards.
David Vomund is an Incline Village-based Independent Investment Advisor. Information is found at http://www.VomundInvestments.com or by calling 775-832-8555. Clients hold the positions mentioned in this article. Past performance does not guarantee future results. Consult your financial advisor before purchasing any security.
Support Local Journalism
Support Local Journalism
Readers around the Lake Tahoe Basin and beyond make the Tahoe Tribune's work possible. Your financial contribution supports our efforts to deliver quality, locally relevant journalism.
Now more than ever, your support is critical to help us keep our community informed about the evolving coronavirus pandemic and the impact it is having locally. Every contribution, however large or small, will make a difference.
Your donation will help us continue to cover COVID-19 and our other vital local news.
Start a dialogue, stay on topic and be civil.
If you don't follow the rules, your comment may be deleted.
User Legend: Moderator Trusted User